Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours
NCT ID: NCT03262207
Last Updated: 2017-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2016-09-30
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of this study is to determine whether patients with seminomas in comparison with fertile men carry a higher risk of presenting epigenetic alterations affecting their gametes.
This study is based on the use of an existing collection of biological samples. 90 samples will be selected and split into 3 groups:
* Group 1: 30 sperm samples from patients with seminomatous testicular tumours
* Group 2: 30 sperm samples from fertile patients
* Group 3: 30 sperm samples from infertile patients
After treatment of the samples (thawing, cell sorting and removal of cryoprotectants), they will be analysed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Transposon Control Pathways in Germinal Cancers of the Testicle
NCT02873793
Characterization of Methylation Pattern in Human Germ Cells of Patients Undergoing ICSI Treatment
NCT03565107
Epigenetic Safety of Assisted Reproductive Technology
NCT04065945
Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans
NCT02171845
Preimplantation Genetic Screening (PGS) in Advanced Female Age and Male Severe Factor
NCT01571076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
testicular tumours
Extraction genomic DNA
Analysis of methylation profiles of numerous GSI and TE
Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)
Method of protein detection by immunostaining and flow cytometry
fertile
Extraction genomic DNA
Analysis of methylation profiles of numerous GSI and TE
Method of protein detection by immunostaining and flow cytometry
infertile
Extraction genomic DNA
Analysis of methylation profiles of numerous GSI and TE
Method of protein detection by immunostaining and flow cytometry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extraction genomic DNA
Analysis of methylation profiles of numerous GSI and TE
Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)
Method of protein detection by immunostaining and flow cytometry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* biological samples of patients over 18 years old
* with testicular tumours/Fertile/Infertile
* Matched for age with patients suffering from testicular tumours
Exclusion Criteria
* biological samples from patients with chronic hepatitis B or C or HIV infection
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DESCH AOI 2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.